Skip to content
NBlaz – Lifestyle
Author:
Entera Bio Ltd.
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis – Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
May 8, 2026
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
April 14, 2026
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
April 2, 2026